We previously reported linkage of a prostate cancer tumor aggressiveness locus to chromosome 7q32-q33, a region also associated with a high frequency of allelic imbalance in prostate tumors. The smallest region of allelic imbalance contains the gene podocalyxin-like (PODXL), which we evaluate here as a candidate prostate cancer aggressiveness gene mapping to 7q32-q33. DNA from probands of linked families was examined for germ-line mutations in PODXL. A variable in-frame deletion, four missense and two nonsense variants were identified in linked men. Variants that affected amino acid sequence were further evaluated for association with risk of prostate cancer and tumor aggressiveness in a family-based case-control population 587T) (OR = 1.48, 95% CI = 1.02-2.14, p = 0.04). These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33.
INTRODUCTION
The aggressiveness of prostate cancer varies widely among patients, with some cancers rapidly progressing to invasive, life-threatening disease, while others remain indolent for many years. The mechanisms underlying this variability in disease presentation and course are not known, but there is evidence that genetics may play a role as prostate cancer tumor aggressiveness is influenced by a family history of this disease (1) (2) (3) (4) .
To identify genes that affect the aggressiveness of prostate cancer, we previously performed a genome-wide scan of 594 affected siblings using Gleason score as a surrogate for tumor aggressiveness, and reported strong linkage to chromosome 7q32-q33 (5, 6) . Linkage to this region has been replicated in two independent studies (7, 8) , and a third report has linked a neighboring region on chromosome 7q to prostate cancer susceptibility among 36 Jewish families (9) . Chromosome 7q32-q33 has also been shown to exhibit a high frequency of allelic imbalance in prostate tumors, with the smallest region of allelic imbalance spanning approximately 1.1 Mb and corresponding to the peak linkage marker from our affected sibling pair study (5, 6, 8) . pathway between neighboring podocyte foot processes by charge repulsion (11) . In the vasculature, podocalyxin acts as an adhesion molecule on high endothelial venules, supporting the tethering and rolling of lymphocytes through binding to L-selectin (12) .
Podocalyxin has been implicated in the development of cancer and, in particular, more aggressive cancer. Podocalyxin is a downstream target gene of the WT1 tumor suppressor (13, 14) , and has been implicated in beta catenin signaling (15). Studies have also shown that podocalyxin expression is negatively regulated by TP53 in kidney cells (16) . Recent data has shown a correlation between high levels of podocalyxin protein expression and a more aggressive breast cancer (17) .
Furthermore, gene expression studies have implicated podocalyxin in angiogenesis, where a positive correlation was seen between expression of PODXL and ETS1, a regulator of angiogenesis, in human vascular endothelial cells (HUVECs) (18) . Additionally, podocalyxin was recently reported commonly expressed by blasts in both acute myeloid and acute lymphoblastic leukemias (19) .
The linkage and allelic imbalance studies noted above, along with the known functions of podocalyxin, make it an attractive candidate gene for involvement in tumor aggressiveness. To assess the potential role of podocalyxin in prostate cancer risk, we first performed PODXL germline mutation analyses of probands from families linked to chromosome 7q32-q33 (5). We then evaluated the relationship between these PODXL variants and prostate cancer and tumor aggressiveness in a family-based association study. A variable in-frame deletion and a missense variant of PODXL were both associated with risk of prostate cancer and tumor aggressiveness. 
RESULTS

PODXL variants in families linked to chromosome 7q32-q33
Mutation analyses of PODXL were performed by DNA sequencing using genomic DNA from white blood cells of probands of the 17 families that showed linkage to chromosome 7q32-q33. Primers were designed to amplify all 8 exons of PODXL including the intron splice donor and acceptor regions (Table 1) . A number of coding sequence variants in PODXL were identified (Table 2) . Specifically, we identified a common variable in-frame deletion, four common missense variants, two silent variants and two intronic substitutions (g.IVS4-51 T>C and g.IVS6+6 C>T). The variable in-frame deletion in exon 1 was 6bp (TCGCCG) or 12bp
(TCGCCGTCGCCG) nucleotides in length (herein termed del6 and del12), and resulted in the loss of one or two serine-proline repeats (two or four amino acid residues, respectively). The inframe deletion variant, and missense variants 340G>A, 587C>T and 802C>G were genotyped in the case-control population. A reliable assay for the 982G>A variant could not be developed and was not investigated further.
Allele frequencies for PODXL variants in a family-based case-control population
Allele frequencies of the PODXL variants in the case-control population are shown in Table 3 . Three cases were not successfully genotyped in the case-control population and were not included in the results. Note that a third form of the in-frame deletion, a deletion of 18bp (TCGCCGTCGCCGTCGCCG) (herein termed del18) was identified in our case-control population but was not observed in our original 17 linked families. The del18 deletion occurs at the same locus as the del6 and del12 deletions and results in the loss of an additional serine- Combining the deletion genotypes, the presence of any single deletion gave an OR = 3.04 (95% CI = 1.01-9.15, p = 0.05), and carrying two copies of any deletion gave an OR = 4.42 (95% CI = 1.32-14.85, p = 0.02) ( Table 4 , lower panels). No association was found between any deletion and prostate cancer among men with less aggressive disease (not shown).
Analysis of the G340A variant suggested that carrying one or two of the G340A variants increased prostate cancer risk by approximately 50% (Table 5) We observed a positive association between men carrying one or two deletion copies and prostate cancer, which was strengthened among men with more advanced disease. The corresponding odds ratios suggest that carrying two copies of the variable in-frame deletion doubles a man's risk of developing more aggressive prostate cancer. We also identified an 18bp deletion (del18) in PODXL that was found predominantly in African
American men and appears to be a founder mutation in this population. African American men are of particular interest since they are at higher risk of developing more aggressive forms of prostate cancer compared to other ethnic groups (20) . Unfortunately, our African American population was too small to determine any associations with this variant, and additional studies focused on clarifying the relationship between the del18 variant and prostate cancer risk in African American men are warranted.
The mechanism by which these variants may affect podocalyxin function and subsequently risk of prostate cancer progression is not known. However, insight into a possible mechanism may come from studies of podocalyxin in the kidney where it plays a critical role in kidney architecture through the maintenance of foot processes and filtration slits through its highly negatively charged extracellular domain. This essential role of podocalyxin in the kidney was demonstrated in Podxl -/-null mice where pups died within 24 hours of birth with severe podocyte dysfunction and renal failure (10) . This membrane stabilization of podocytes is maintained through a membrane-cytoskeleton-associated complex involving PODXL, Na+/H+-exchanger regulatory factor 1/2 (NHERF1/2), the metastasis-associated protein EZRIN and Factin (21, 22) .
Ezrin plays a critical role in a number of signaling pathways implicated in metastasis (23-29). However, it remains to be proven whether the variable in-frame deletion we report in PODXL has any affect on function of the podocalyxin protein.
There is a precedent for the association of a common in-frame deletion in a protein and risk of developing cancer: transforming growth factor-beta receptor, Type I (TGFBR1) (36) . A common variant (TGFBR1*6A), which results in the loss of three alanine amino acids within a nine alanine repeat at the end of exon 1 of TGFBR1, results in a reduction in the anti-proliferative effects of TGF beta (37, 38) . This variant (TGFBR1*6A) has been associated with increased risk of a number of malignancies including, breast, colon and other cancers (37) (38) (39) (40) (41) (42) (43) (44) .
In summary, we report an association between two PODXL variants and increased risk of developing prostate cancer and increased tumor aggressiveness. Our data suggest that individually, or in concert, PODXL variants, or variants on their haplotypes, may alter the
MATERIALS AND METHODS
Study subjects used in mutation studies
Seventeen probands from brother-pairs that showed strong linkage with D7S1804, the peak linkage marker in our original sibling-pair study (5), were chosen for mutation analysis.
Marker D7S1804 was chosen because it also mapped to the distal boundary of the smallest common region of allelic imbalance found in prostate tumors (6) . The 17 families showed mean allele sharing between brothers of greater than 70% (with 11 of the 17 families sharing at greater than 95%) at marker D7S1804 with respect to Gleason score. Mutation analyses were performed on DNA isolated from blood leukocytes. Details about recruitment of the subjects that were included in the original linkage analysis are reported in Suarez et al (45) .
Study subjects used in association studies
The family-based case-control study population was recruited through the major medical institutions in the Greater Cleveland, Ohio area and from the Henry Ford Health System in Detroit, Michigan between 1998 and 2001. Men with histologically confirmed prostate cancer were invited to join the study if they fulfilled specific criteria. That is, they were diagnosed at 73 years or younger and had a living, unaffected brother who was either older or at most eight years younger than their age at diagnosis. These criteria were selected in an attempt to increase the likelihood of detecting genetic factors influencing prostate cancer and to minimize potential for misclassification of prostate cancer status amongst controls. We chose to use this sibling-based study design to ensure that our control group was selected from the same genetic source population as the cases, and thus not to be subject to population stratification from factors such as ethnicity. The clinical characteristics (e.g. Gleason score, tumor stage) of each case were obtained from medical records. Prostate specific antigen (PSA) levels were measured for all potential controls to screen for possible asymptomatic disease. If a control had PSA levels above 4 ng/ml, they were informed and advised by our collaborating urologists that they should schedule an appointment with their primary care physicians to further evaluate this finding. Such individuals were retained in the study as controls unless a subsequent diagnosis of prostate cancer was made.
Their inclusion in the study is important because automatically excluding men with elevated PSA levels regardless of their ultimate prostate cancer status can lead to biased estimates of association (46, 47).
A total of 918 men (439 cases and 479 controls) were included in the present study. Each proband had at least one unaffected brother, with some families having multiple affected and unaffected brothers. Ninety-one percent of the subjects were Caucasian, 8% were African American and 1% were Asian or Latino. The mean age at diagnosis of the cases was 61 years and the mean age of controls at enrollment was 62.7 years. This study was approved by the Institutional Review Boards of all participating institutions and all study participants provided written informed consent.
Mutation analysis of PODXL
Genomic DNA samples from the probands of 17 families that showed linkage to chromosome 7q32-q33 were subjected to mutation analyses of the PODXL gene by DNA sequencing. Primers used to amplify all 8 exons including the intron splice donor and acceptor Arbor, MI).
PODXL genotyping
Several coding sequence variants were identified in PODXL and these are shown in Table   2 . Genotyping was performed on those variants that affected amino acid sequence. The PODXL variable in-frame deletion in exon 1 was genotyped following PCR amplification using the primers 5'-CTCCTCTGCCACTGGCTCTG-3' and 5'-CGTGGATGGTGCAAGGTCAG. The forward primer included a 5' fluorophore for analysis using a MegaBACE 1000 DNA analysis system. Allele sizes were assessed using Genetic Profiler v1.5 software (Amersham Biosciences, Piscataway). Two additional variants (rs15956 and rs1733877) within the PODXL gene region were genotyped using pre-made TaqMan assays (Applied Biosystems). Reactions were performed according to manufacturers instructions using the RealMasterMix Probe (+ROX) kit (Eppendorf) and genotypes determined using a Prism 7900HT instrument (Applied Biosystems). For simplification, the genotype counts shown reflect the number of sibling pairs with specific case-control combinations of genotypes. If there is more than one case and one control in a family, all possible combinations of the sibling-pairs are included. Bold counts indicate pairs where a case carries more copies of the variant than the control and bold and italicized counts the opposite. The difference between these drives the association with prostate cancer. For the Odds Ratios shown above, sibling sets are treated appropriately by conditional logistic regression in that each family is analyzed as a matched set, so all men are only counted once in the analysis. This regression provides estimate of odds ratios and 95% confidence intervals comparing men with one or two PODXL exon 1 in frame deletions to those with none (adjusted for age). a Adjusted for age. OR = odds ratio. CI = confidence intervals. b Deletions of any length. c Includes cases with Gleason score ≥ 7 or Tumor stage ≥T2C and their brothers.
